INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.18 USD | -1.08% |
|
-3.10% | -18.49% |
| Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -18.49% | 11.62B | B- | ||
| -2.86% | 87.31B | A- | ||
| +2.63% | 40.86B | A- | ||
| -21.76% | 29.36B | B- | ||
| +58.56% | 24.49B | A | ||
| -14.78% | 17.31B | C | ||
| -15.61% | 11.31B | D+ | ||
| -44.02% | 11.26B | B | ||
| +5.17% | 8.31B | B+ | ||
| -9.82% | 7.9B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- INCY Stock
- Ratings Incyte Corporation
